The Outcome of Fungal Pneumonia with Hematological Cancer
1
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background: Fungal pneumonia is a common infectious complication of hematological cancer (HC) patients. In this retrospective study, the objective was set to identify the risk factors and outcome of fungal pneumonia in adult HC patients. Materials and Methods: This retrospective study was conducted with adult (>16 years) HC patients from January 2017 and December 2018. Results: During the study period, of 181 patients included 76 were diagnosed with fungal pneumonia. The most common HC was identified as acute myeloid leukaemia (40%). Of the participating patients, 52 (29%) were hematopoietic stem cell transplant (HSCT) recipients. The median age of patients with fungal pneumonia was significantly greater: 57 vs. 48 (odds ratio [OR]: 1.08) and they had longer hospitalization durations (OR: 1.14). Overall, 37 patients (20%) died, and 28-day mortality was significantly greater among patients with fungal pneumonia than without fungal pneumonia (33% vs. 11%). The most significant risk factors for mortality in fungal pneumonia were identified as need of intensive care unit (ICU) (OR: 191.2, P <0.001) and the need of vasopressor support (OR:81.6, P <0.012). ICU-mortality was (88%). Conclusion: Fungal pneumonia is a lethal complication in HC patients. Intensive care need is the most important predictive factor for mortality
Abstract
Background: Fungal pneumonia is a common infectious complication of hematological cancer (HC) patients. In this retrospective study, the objective was set to identify the risk factors and outcome of fungal pneumonia in adult HC patients. Materials and Methods: This retrospective study was conducted with adult (>16 years) HC patients from January 2017 and December 2018. Results: During the study period, of 181 patients included 76 were diagnosed with fungal pneumonia. The most common HC was identified as acute myeloid leukaemia (40%). Of the participating patients, 52 (29%) were hematopoietic stem cell transplant (HSCT) recipients. The median age of patients with fungal pneumonia was significantly greater: 57 vs. 48 (odds ratio [OR]: 1.08) and they had longer hospitalization durations (OR: 1.14). Overall, 37 patients (20%) died, and 28-day mortality was significantly greater among patients with fungal pneumonia than without fungal pneumonia (33% vs. 11%). The most significant risk factors for mortality in fungal pneumonia were identified as need of intensive care unit (ICU) (OR: 191.2, P <0.001) and the need of vasopressor support (OR:81.6, P <0.012). ICU-mortality was (88%). Conclusion: Fungal pneumonia is a lethal complication in HC patients. Intensive care need is the most important predictive factor for mortality
참고문헌 (22)
- Dizon DS, "Clinical Cancer Advances 2016 : Annual Report on Progress Against Cancer From the American Society of Clinical Oncology", J Clin Oncol, 34, pp.987~1011 (2016)
- Atkins S, "Chemotherapy and beyond : infections in the era of old and new treatments for hematologic malignancies", Infect Dis Clin North Am, 33, pp.289~309 (2019)
- Bommart S, "Infectious chest complications in haematological malignancies", Diagn Interv Imaging, 94, pp.193~201 (2013)
- "Gac Med Mex", 2016, 465~472
- Young AY, "Fungal pneumonia in patients with hematologic malignancy and hematopoietic stem cell transplantation", Clin Chest Med, 38, pp.479~491 (2017)
- Rossini F, "Incidence and outcome of fungal pneumonia in patients with acute leukemia receiving first induction therapy with anthracyclinecontaining regimens", Haematologica, 85, pp.1255~1260 (2000)
- Khayr W, "Infections in hematological malignancies", Dis Mon, 58, pp.239~249 (2012)
- De Pauw B, "Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer", Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC, Clin Infect Dis, pp.2008, 46[DOI]
- Magiorakos AP, "Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria : an international expert proposal for interim standard definitions for acquired resistance", Clin Microbiol Infect, 18, pp.268~281 (2012)
- Singer M, "The third international consensus definitions for sepsis and septic shock(sepsis-3)", JAMA, 315, pp.801~810 (2016)
- Verdonk F, "The new sepsis definition : limitations and contribution to research and diagnosis of sepsis", Curr Opin Anaesthesiol, 30, pp.200~204 (2017)
- Zimmerman JE, "Acute physiology and chronic health evaluation(APACHE)IV : hospital mortality assessment for today's critically ill patients", Crit Care Med, 34, pp.1297~1310 (2006)
- Grgić Medić M, "Hematologic malignancies in the medical intensive care unit--Outcomes and prognostic factors", Hematology, 20, pp.247~253 (2015)
- Alp E, "Outcomes for haematological cancer patients admitted to an intensive care unit in a university hospital", Aust Crit Care, 31, pp.363~368 (2018)
- Azoulay E, "Outcomes of critically ill patients with hematologic malignancies : prospective multicenter data from France and Belgium--a groupe de recherche respiratoire en réanimation onco-hématologique study", J Clin Oncol, 31, pp.2810~2818 (2013)
- Song JU, "Early intervention on the outcomes in critically ill cancer patients admitted to intensive care units", Intensive Care Med, 38, pp.1505~1513 (2012)
- Geerse DA, "Prognosis of patients with haematological malignancies admitted to the intensive care unit : sequential organ failure assessment(SOFA)trend is a powerful predictor of mortality", Eur J Intern Med, 22, pp.57~61 (2011)
- Yeo CD, "Prognostic factors in critically ill patients with hematologic malignancies admitted to the intensive care unit", J Crit Care, 27, pp.739.e1~739.e6 (2012)
- Depuydt P, "Outcome in critically ill patients with allogeneic BM or peripheral haematopoietic SCT : a single-centre experience", Bone Marrow Transplant, 46, pp.1186~1191 (2011)
- Taplitz RA, "Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression : ASCO and IDSA clinical practice guideline update", J Clin Oncol, 36, pp.3043~3054 (2018)
- Rambaldi B, "Defining invasive fungal infection risk in hematological malignancies : a new tool for clinical practice", Mediterr J Hematol Infect Dis, 9, pp.e2017012~ (2017)
- de Montmollin E, "Outcomes in critically ill cancer patients with septic shock of pulmonary origin", Shock, 39, pp.250~254 (2013)